Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

TC Tech Sweden AB (publ): TC TECH receives the company's first order in the biotechnology sector from Israel-based diagnostics company Picodya Technologies Ltd. (Picodya)

Picodya is an innovative diagnostics company, which develops solutions to enable rapid and cost effectiveness in vitro diagnostics directly at point of care facilities (POC). Each diagnostic testing for a patient requires the use of advanced consumable products, which needs to be manufactured with high precision to secure efficient and reliable diagnostics.

"I am pleased to present TC TECH's first order in the biotechnology sector, and it's also very suitably coming from a European based company. To be selected as technology provider to an innovative diagnostics company as Picodya is an interesting step for TC TECH and we will be looking forward to further developing our technology together with Picodya for applications within this market segment," says TC TECH's CEO Alexander Luiga.

The order includes a TCP150 HPE RtS production system with expected delivery to the customer already during the end of the second quarter of 2022.

The parties have also initiated discussions on a collaboration agreement to further enhance TC TECH's production technology, with a focus on applications within microfluidics. TC TECH has a positive view on this opportunity to potentially further develop the company's offering in this exciting market segment.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.